Dr Keisuke Horikawa, ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, ANU
Signalling from antigen receptors plays a crucial role in determining the fate of normal lymphocytes. How about malignant lymphocytes, lymphomas? Do they need antigenic stimulation through the B cell receptor for survival or proliferation? My team is addressing this long-standing question using retrovirus gene delivery of lymphoma-associated mutations and self-reactive B cell model. Investigating the consequence of oncogenic mutations in CARD11 and MYD88 revealed that growth and survival of malignant B cells are not as autonomous as previously thought. Our study provides new insights into pathogenesis and potential therapeutic targets for lymphomas.